News

News 11.12.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its...

News 06.12.2023 Washington, D.C., Zürich, Switzerland The Physicians Committee for Responsible Medicine, a nonprofit that advances human-based science, and InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, are pleased to announce the winners of the HUMAIN Award 2023 (Human Advanced In Vitro Model Initiative). The award recognizes researchers working to expand access to and accelerate the...

News 29.11.2023 Schlieren (Zurich), Switzerland, November 28, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be...

News 20.11.2023 Schlieren / Zurich, Switzerland – November 16, 2023 – Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading...

News 14.11.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present on several of its programs at the 15th Annual Protein & Antibody Engineering European...